Growing incidence of pancreatic neuroendocrine tumours (PNET) in Czech Republic

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter J. Barkmanova
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors J. Barkmanova1, M. Zvolsky2, P. Vítek3, E. Sedlackova4
  • 1Dept.of Oncology 1st Faculty of Medicine and General Faculty Hospital Prague, Prague, Czech Republic, /
  • 2Institute of Health Information and Statistics Prague, Prague, Czech Republic, /
  • 3PTC, Prague, Czech Republic, /
  • 4Dept. of Oncology, 1st Faculty of Medicine and General Faculty Hospital Prague, Prague, Czech Republic, /

Abstract

In European population PNETs account for 1-5% of pancreatic tumours by incidence. There is a slight predominance of males. The prognosis is much better compared to common cancer of exocrine pancreas if the patients carrying PNETs receive a particular care in specialized centres. It should not present a substantial problem in 10 million population of Czech Republic unless the incidence does not substantially increase. The trends of PNET incidence in Czech Republic were assessed to estimate the burden of health care system.